Immuno-Precise Antibodies :: IPA Accolades - Customer Satisfaction Guaranteed

Orders: (250) 483-0308 | 1-800-620-4187

Fax: (250) 483-0309

Citations

Peer Reviewed Publications

Review the expanding list of publications sourcing IPA's catalog products & exclusively developed custom mAb hybridomas.

Accolades

Customer Feedback

Listen to what IPA's existing & past customers have to say about our products & custom antibody development services.

Accreditation

National Institutes of Health

IPA is a compliant member by the Office of Laboratory Animal Welfare (OLAW) of the the Department of Health and Human Services (HHS), USA and has been awarded with a 5-year Animal Welfare Assurance Number.

Canadian Council on Animal Care

IPA is a member of the the Canadian Council on Animal Care. The CCAC provides certification and policies on ethical animal care and use.

Better Business Bureau

IPA is a member of the Better Business Bureau. The BBB is a private, non-profit organization, dedicated to promoting fairness and honesty in the marketplace.

Promotions

Save $500.00 on Custom Hybridoma Development!

For a limited time, save $500.00 on custom hybridoma development with ImmunoPrecise.
Limited time offer, expires April 1/08.

Quick Links

Quote Request Form

To expedite receiving a quote from IPA for your custom antibody development project, fill in the on-line submission form or download the following form and email or fax to (250) 483-0309. Quotes issued in less than 24 hrs.

Product Order Form

To order any of IPA's antibody products, download the following form and email or fax to (250) 483-0309. Confirmation in less than 24 hrs.

Antigen Infomation Sheet

To initiate the immunization phase of your custom antibody development project, download the following form and submit it with the shipment of your antigen.

Grant Krafft, PhD

Chairman and Chief Science Officer

Acumen Pharmaceuticals, Inc.

One Northfield Plaza, Suite 460

Northfield, IL 60093

Tel: +1.847.947.3108

Fax: +1.253.498.8329

gkrafft@acumenpharm.com

"The Immuno-Precise 'rapid-prime' antibody technology proved pivotal to Acumen's success, enabling timely identification of the first ADDL selective monoclonal antibodies. Subsequent proof-of-concept studies with our Northwestern colleagues led to our successful Merck collaboration to develop effective therapeutic antibodies for Alzheimer's disease."

Douglas McAllister, Ph.D. - President

ViroStat, Inc.

P.O. Box 8522

Portland, Maine USA 04104

Tel: +1.207.856.6620

Fax: +1.207.856.6864

dougmc@biode.com

A number of the monoclonal antibodies developed for us by Immuno-Precise Antibodies Ltd. are currently in use by several of our commercial clients in their rapid, point of care tests for infectious disease detection. This speaks to the fact that these antibodies are of the strictest specificities and highest affinities available.

Dr. R.Gorczynski, MD PhD, Professor

University Health Network,

MaRS Centre, Toronto Medical Discovery Tower

101 College Street, 2nd Floor, Rm.805

Toronto, Ontario, M5G1L7

Tel: +1.416.581.7519

Fax: +1.416.581.7515

reg.gorczynski@utoronto.ca

"The monoclonal antibodies developed for us by Immuno-Precise Antibodies Ltd. over the past 5-10 years have been instrumental in providing proof-of-concept data for our research, which in turn has excited considerable commercial interest. Their reagents have always been developed promptly, tested to have the strict specificities we requested, and to have the highest affinities available. We would never consider another company to approach for outsourcing our monoclonal development."

Website Designed by Irtus Software Inc.